Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
CA Luke, MYS Moosa, TM Esterhuizen, SE Knight, S Saman & A Ross. (2014) Lactic acidosis, risk factors and predictive laboratory markers: a nested case control study in South Africa. South African Family Practice 56:1, pages 63-68.
Read now
Read now
Maria Gracia Mateo, Maria del Mar Gutierrez, Francesc Vidal & Pere Domingo. (2012) Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. Expert Opinion on Drug Safety 11:3, pages 473-485.
Read now
Read now
Adrian Curran & Esteban Ribera. (2011) From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opinion on Drug Safety 10:3, pages 389-406.
Read now
Read now
Alain Makinson, Vincent Le Moing, Charles Kouanfack, Christian Laurent & Eric Delaporte. (2008) Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opinion on Drug Safety 7:3, pages 283-293.
Read now
Read now
Articles from other publishers (49)
Andy Kuo, Janet R. Nicholson, Laura Corradini & Maree T. Smith. (2019) Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methods. Inflammopharmacology 27:2, pages 387-396.
Crossref
Crossref
Willem Daniel Francois Venter, Andrew Kambugu, Matthew F. Chersich, Stephen Becker, Andrew Hill, Natasha Arulappan, Michelle Moorhouse, Mohammed Majam, Godspower Akpomiemie, Simiso Sokhela, Selvamuthu Poongulali, Charles Feldman, Chris Duncombe, David H. Brown Ripin, Alinda Vos & Nagalingeswaran Kumarasamy. (2019) Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 80:2, pages 224-233.
Crossref
Crossref
Alinda G. Vos, Matthew F. Chersich, Kerstin Klipstein-Grobusch, Peter Zuithoff, Michelle A. Moorhouse, Samanta T. Lalla-Edward, Andrew Kambugu, N. Kumarasamy, Diederick E. Grobbee, Roos E. Barth & Willem D. Venter. (2018) Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir. Retrovirology 15:1.
Crossref
Crossref
Cecile Cames, Lea Pascal, Aissatou Ba, Hélène Mbodj, Baly Ouattara, Ndeye-Fatou Diallo, Philippe Msellati, Ngagne Mbaye, Haby Sy Signate, Stephane Blanche & Aminata Diack. (2018) Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study. BMC Infectious Diseases 18:1.
Crossref
Crossref
Steve Innes, Louvina van der Laan, Peter L. Anderson, Mark Cotton & Paolo Denti. (2018) Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. Antimicrobial Agents and Chemotherapy 62:11.
Crossref
Crossref
Steve Innes, Justin Harvey, Intira Jeannie Collins, Mark Fredric Cotton & Ali Judd. (2018) Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland. PLOS ONE 13:4, pages e0194132.
Crossref
Crossref
Marta Boffito, Mohammed Lamorde, Melynda Watkins & Anton Pozniak. (2017) Antiretroviral dose optimization. Current Opinion in HIV and AIDS 12:4, pages 339-342.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
483
488
.
José Moltó, Marta Valle, Elena Ferrer, Pere Domingo, Adrian Curran, José Ramón Santos, María Gracia Mateo, María Silvana Di Yacovo, Cristina Miranda, Daniel Podzamczer, Bonaventura Clotet, Bonaventura Clotet, Josep Coll, Silvia Gel, Josep Maria Llibre, Cristina Miranda, José Moltó, Beatriz Mothe, Eugenia Negredo, Nuria Pérez-Álvarez, José Ramón Santos, Guillem Sirera, María Silvana DiYacovo, Elena Ferrer, Daniel Podzamczer, Nerea Rozas, Antonia Vila, Pere Domingo, María Del Mar Gutiérrez, Gracia Mateo, Marta Valle, Joaquín Burgos, Adrian Curran, Jordi Navarro & Esteban Ribera. (2015) Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. Journal of Antimicrobial Chemotherapy 70:4, pages 1139-1145.
Crossref
Crossref
Sherwin K.B. Sy, Ruben Malmberg, Aoi Matsushima, Eduardo Asin-Prieto, Bernd Rosenkranz, Mark F. Cotton, Hartmut Derendorf & Steve Innes. (2015) Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. International Journal of Antimicrobial Agents 45:4, pages 413-419.
Crossref
Crossref
Nombulelo Magula & Martin Dedicoat. (2015) Low dose versus high dose stavudine for treating people with HIV infection. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Julia L Finkelstein, Pooja Gala, Rosemary Rochford, Marshall J Glesby & Saurabh Mehta. (2015) HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings. Journal of the International AIDS Society 18:1, pages 19033.
Crossref
Crossref
Todd Hulgan, Rebecca T. Levinson, Mariana Gerschenson, Nittaya Phanuphak, Jintanat Ananworanich, Nipat Teeratakulpisarm, Tanate Jadwattanakul, Daniel E. LiButti, Heidi Fink, Justin C. McArthur, Gigi J. Ebenezer, Peter Hauer, Deborah Murdock, Cecilia M. Shikuma & David C. Samuels. (2014) Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy. AIDS 28:11, pages 1625-1633.
Crossref
Crossref
Sherwin K. B. Sy, Steve Innes, Hartmut Derendorf, Mark F. Cotton & Bernd Rosenkranz. (2014) Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. Antimicrobial Agents and Chemotherapy 58:2, pages 1084-1091.
Crossref
Crossref
CN Menezes, NJ Crowther, R Duarte, D Van Amsterdam, D Evans, C Dickens, T Dix-Peek, M Rassool, A Prinsloo, F Raal & I Sanne. (2014) A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Medicine 15:1, pages 3-12.
Crossref
Crossref
Mikaela Smit, Colette Smit, Suzanne Geerlings, Luuk Gras, Kees Brinkman, Timothy B. Hallett & Frank de Wolf. (2013) Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands. PLoS ONE 8:9, pages e76071.
Crossref
Crossref
CN Menezes, R Duarte, C Dickens, T Dix‐Peek, D Van Amsterdam, M‐A John, P Ive, M Maskew, P MacPhail, MP Fox, F Raal, I Sanne & NJ Crowther. (2012)
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial
DNA
copy number and metabolic parameters in
S
outh
A
frican
HIV
‐infected patients: a randomized trial
. HIV Medicine 14:4, pages 217-225.
Crossref
Crossref
Sandro Vento, Massimiliano Lanzafame, Emanuela Lattuada, Francesca Cainelli, Umberto Restelli & Emanuela Foglia. (2012) Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries. Tropical Medicine & International Health 18:1, pages 40-44.
Crossref
Crossref
Marco Vitoria, Stefano Vella & Nathan Ford. (2013) Scaling up antiretroviral therapy in resource-limited settings. Current Opinion in HIV and AIDS 8:1, pages 12-18.
Crossref
Crossref
Steve Innes, Mark F Cotton, Richard Haubrich, Maria M Conradie, Margaret van Niekerk, Clair Edson, Helena Rabie, Sonia Jain, Xiaoying Sun, Ekkehard W Zöllner, Stephen Hough & Sara H Browne. (2012) High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatrics 12:1.
Crossref
Crossref
Nittaya Phanuphak, Jintanat Ananworanich, Nipat Teeratakulpisarn, Tanate Jadwattanakul, Stephen J Kerr, Nitiya Chomchey, Piranun Hongchookiat, Pornpen Mathajittiphun, Suteeraporn Pinyakorn, Patcharawee Rungrojrat, Pairoa Praihirunyakit, Mariana Gerschenson, Praphan Phanuphak, Victor Valcour, Jerome H Kim & Cecilia Shikuma. (2012) A 72-Week Randomized Study of the Safety and Efficacy of a Stavudine to Zidovudine Switch at 24 Weeks Compared to Zidovudine or Tenofovir Disoproxil Fumarate when Given with Lamivudine and Nevirapine. Antiviral Therapy 17:8, pages 1521-1531.
Crossref
Crossref
Mark A Boyd & David A Cooper. (2012) Optimisation of HIV care and service delivery: doing more with less. The Lancet 380:9856, pages 1860-1866.
Crossref
Crossref
Keith W Crawford, David H Brown Ripin, Andrew D Levin, Jennifer R Campbell & Charles Flexner. (2012) Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. The Lancet Infectious Diseases 12:7, pages 550-560.
Crossref
Crossref
Mhairi Maskew, Daniel Westreich, Matthew P Fox, Thapelo Maotoe & Ian M Sanne. (2012) Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV‐infected adults initiating HAART in South Africa. Journal of the International AIDS Society 15:1, pages 13-13.
Crossref
Crossref
George P. H. Leung. 2012. Advances in Mitochondrial Medicine. Advances in Mitochondrial Medicine
347
369
.
Mar Pujades-Rodríguez, Emmanuelle Dantony, Loretxu Pinoges, René Ecochard, Jean-François Etard, Esther Carrillo-Casas & Elisabeth Szumilin. (2011) Toxicity Associated with Stavudine Dose Reduction from 40 to 30 mg in First-Line Antiretroviral Therapy. PLoS ONE 6:11, pages e28112.
Crossref
Crossref
Pedro Cahn, Julio Montaner, Patrice Junod, Patricia Patterson, Alejandro Krolewiecki, Jaime Andrade-Villanueva, Isabel Cassetti, Juan Sierra-Madero, Arnaldo David Casiró, Raul Bortolozzi, Sergio Horacio Lupo, Nadia Longo, Emmanouil Rampakakis, Nabil Ackad & John S. Sampalis. (2011) Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen. PLoS ONE 6:8, pages e23726.
Crossref
Crossref
Esteban Ribera, Montse Tuset, Maite Martín & Elena del Cacho. (2011) Características de los fármacos antirretrovirales. Enfermedades Infecciosas y Microbiología Clínica 29:5, pages 362-391.
Crossref
Crossref
Andrew Hill. (2010) d4T: keep it or abandon it?. Asian Biomedicine 4:4, pages 541-546.
Crossref
Crossref
Natasza E. Ziółkowska, Christopher J. Michejda & Grzegorz D. Bujacz. (2010) Structural studies of series HIV-1 nonnucleoside reverse transcriptase inhibitors 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)-benzimidazoles with different 4-substituents. Journal of Molecular Structure 966:1-3, pages 53-58.
Crossref
Crossref
Johan van Griensven, Rony Zachariah, Freya Rasschaert, Jules Mugabo, Edi F. Atté & Tony Reid. (2010) Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene 104:2, pages 148-153.
Crossref
Crossref
Nathan Ford & Alexandra Calmy. (2010) Improving first-line antiretroviral therapy in resource-limited settings. Current Opinion in HIV and AIDS 5:1, pages 38-47.
Crossref
Crossref
Natasza E. Ziółkowska, Christopher J. Michejda & Grzegorz D. Bujacz. (2010) Structure of HIV-1 nonnucleoside reverse transcriptase inhibitors derivatives of N-benzyl-benzimidazole with different substituents in position 4. Journal of Molecular Structure 963:2-3, pages 188-193.
Crossref
Crossref
Oliver Koch, Susanne Sheehy, Catherine Sargent, Jane Democratis, Sarah Abbas, Jurgen Schiefermueller & Brian J. Angus. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
529
553
.
Mark Boyd & David A. Cooper. 2010. Antibiotic and Chemotherapy. Antibiotic and Chemotherapy
427
451
.
Maurizio Bevilacqua, Ligia J. Dominguez & Mario Barbagallo. (2009) Insulin Resistance and the Cardiometabolic Syndrome in HIV Infection. Journal of the CardioMetabolic Syndrome 4:1, pages 40-43.
Crossref
Crossref
Natasza E. Ziółkowska, Christopher J. Michejda & Grzegorz D. Bujacz. (2009) Structural investigation of HIV-1 nonnucleoside reverse transcriptase inhibitors: 2-Aryl-substituted benzimidazoles. Journal of Molecular Structure 937:1-3, pages 34-38.
Crossref
Crossref
Ravindra K. Gupta & Brian J. Angus. 2009. Evidence‐Based Infectious Diseases. Evidence‐Based Infectious Diseases
177
205
.
Christopher J Hoffmann, Salome Charalambous, Katherine L Fielding, Craig Innes, Richard E Chaisson, Alison D Grant & Gavin J Churchyard. (2009) HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. AIDS 23:13, pages 1784-1786.
Crossref
Crossref
Andrew Hill. (2012) The ABC of HIV Clinical Trials. Pharmaceutical Medicine 23:4, pages 201-211.
Crossref
Crossref
Asha R Kallianpur & Todd Hulgan. (2009) Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics 10:4, pages 623-637.
Crossref
Crossref
John A BartlettVenance P Maro. (2009) Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution. HIV Therapy 3:2, pages 109-111.
Crossref
Crossref
Alexandra Calmy, Bernard Hirschel, David A Cooper & Andrew Carr. (2008) A new era of antiretroviral drug toxicity. Antiviral Therapy 14:2, pages 165-179.
Crossref
Crossref
Alexandra Calmy, Cecilia Pizzocolo, Louis Pizarro, Gilles Brücker, Robert Murphy & Christine Katlama. (2008) The marriage of science and optimized HIV care in resource-limited settings. AIDS 22:17, pages 2227-2230.
Crossref
Crossref
Nombulelo Magula & Martin Dedicoat. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
G. A. McComsey, V. Lo Re, III, M. O’Riordan, U. A. Walker, D. Lebrecht, E. Baron, K. Mounzer & I. Frank. (2008) Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV‐Infected Subjects: A Randomized, Controlled Study. Clinical Infectious Diseases 46:8, pages 1290-1296.
Crossref
Crossref
Lisa R. Hirschhorn, Bisola Ojikutu & William Rodriguez. (2007) Research for Change: Using Implementation Research to Strengthen HIV Care and Treatment Scale‐Up in Resource‐Limited Settings. The Journal of Infectious Diseases 196:s3, pages S516-S522.
Crossref
Crossref
Graham S Cooke. (2007) Evolution of adult antiretroviral therapy for programmatic delivery in Africa and the potential role for new therapeutic approaches. Therapy 4:6, pages 767-774.
Crossref
Crossref
Pablo Labarga & Vicente Soriano. (2007) Estavudina en el tratamiento antirretroviral. Medicina Clínica 129:10, pages 375-376.
Crossref
Crossref